Logo Image
Opinion|Videos|November 19, 2024

Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

This episode reviews the response rates reported in the HERTHENA-Lung01 trial among patients with advanced NSCLC exhibiting various resistance mechanisms, evaluates the clinical significance of responses to HER3-DXd based on HER3 expression scores, discusses the relevance of the reported overall DOR, median PFS, and OS, and examines the CNS ORR among patients with baseline brain metastases in relation to the ORRs.

Episodes in this series

Video content above is prompted by the following:

  • Please share your impressions of the response rates reported in HERTHENA-Lung01 among patients with EGFR-dependent, EGFR-independent, or both EGFR-dependent and -independent resistance mechanisms in advanced or metastatic NSCLC.
  • How clinically meaningful are the responses to HER3-DXd across a range of pretreatment, HER3 expression scores in patients with heavily pretreated ,advanced, or metastatic NSCLC?
  • Please comment on the overall 6.4-month DOR, median PFS of 5.5 months, and OS of 11.9 months reported in HERTHENA-Lung01. Are these data meaningful to you?
  • Please share your thoughts on the CNS ORR of 33.3% among the 10 study subjects with baseline brain metastases who attained CR or PR vis-à-vis the confirmed ORR of 29.8%.

Related to this article

View more